Teva Global Specialty Medicines CEO: 70% of US patients currently receiving Copaxone take the 40 mg/mL formulation.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that the Russian Ministry of Health has approved the Marketing Authorization license (MA) for three-times-a-week Copaxone (glatiramer acetate injection) 40 mg/mL. This formulation of the multiple sclerosis treatment will allow for a less frequent dosing regimen for patients with the illnessin Russia.
Teva president and CEO of Global Specialty Medicines Rob Koremans said, “The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for the multiple sclerosis patient community in Russia. The new three-times-a-week Copaxone 40 mg/mL is the same therapy that patients and physicians know and trust with almost 60% fewer injections per year compared to the current daily Copaxone 20 mg/mL formulation. In the US., for example, more than 70% of patients currently receiving glatiramer acetate treatment are receiving the Copaxone 40 mg/mL formulation.”
Daily Copaxone 20 mg, approved in Russia in 2010, continues to be available in Russia.
Published by Globes [online], Israel business news - www.globes-online.com - on October 8, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015
Copaxone